Even in the most sexually liberated and self-satisfied of nations, many people still yearn to burn more, to feel ready for bedding no matter what the clock says and to desire their partner of 23 years as much as they did when their love was brand new.
The market is saturated with books on how to revive a flagging libido or spice up monotonous sex, and sex therapists say "lack of desire" is one of the most common complaints they hear from patients, particularly women.
And though there may be legitimate sociological or personal underpinnings to that diminished desire — chronic overwork and stress, a hostile workplace, a slovenly or unsupportive spouse — still the age-old search continues for a simple chemical fix, Cupid encapsulated, a thrill in a pill.
PHOTO: NY TIMES NEWS SERVICE
Since the spectacular success of Viagra and similar drugs, the pharmaceutical industry has been searching for the female equivalent of Viagra — a treatment that would do for women's most common sexual complaint, lack of desire, what sildenafil did for men's, erectile dysfunction.
Initial trials of Viagra in women proved highly disappointing. True, the drug enhanced engorgement of vaginal tissue, just as it had of the penis, but that extra bit of pelvic swelling did nothing to amplify women's desire for or enjoyment of sex.
What is needed for the treatment of so-called female hypoactive sexual desire disorder, researchers decided, is a reasonably safe and effective drug that acts on the central nervous system, on the pleasure centers of the brain or the sensory circuitry that serves them.
For a while, many sex therapists and doctors were optimistic about Procter & Gamble's Intrinsa, a testosterone patch that delivers small transdermal pulses of the sex hormone thought to play a crucial if poorly understood role in male and female libido alike. But in 2005, the US Food and Drug Administration refused to approve Intrinsa, declaring that its medical risks outweighed whatever modest and spotty benefits it might offer.
More recently, another potentially promising treatment for hypoactive desire has been making its way through clinical trials. The compound, called bremelanotide, is a synthetic version of a hormone involved in skin pigmentation, and it was initially developed by Palatin Technologies of New Jersey as a potential tanning agent to help prevent skin cancer. But when male college students participating in early safety tests began reporting that the drug sometimes gave them erections, the company began exploring bremelanotide's utility as a treatment for sexual disorders.
Studies in rodents demonstrated that the drug not only gave male rats spontaneous erections, but also fomented sexual excitement in female rats, prompting them to wiggle their ears, hop excitedly, rub noses with males and otherwise display unmistakable hallmarks of rodent arousal.
Importantly, the females responded to the drug only under laboratory conditions where they could maintain a sense of control over the mating game. Take away the female's opportunity to escape or proceed at her preferred pace, and no amount of bremelanotide would get those ears to wiggle. In other words, Annette M. Shadiack, director of biological research of Palatin, said, "this doesn't look like a potential date-rape drug."
Inspired by the rodent work, the company decided to give the drug a whirl on women. Results from a pilot study of 26 postmenopausal women with diagnoses of sexual arousal disorder suggest that bremelanotide may well have some mild aphrodisiacal properties.
Responding to questionnaires after taking either the drug or a dummy pill, 73 percent of the women on bremelanotide reported feeling genitally aroused, compared with 23 percent given the placebo; and 43 percent of the bremelanotide group said the treatment augmented their sexual desire, against only 19 percent of those on dummy pills.
Women in the treatment group also were slightly more likely to have sex with their partners during the course of the trial than were those in the control group, although who initiated the romps was not specified.
Larger trials of the drug at some 20 clinical centers around the US are now under way. Among other things, the researchers will try adjusting the dosage to see if more bremelanotide may provoke a more robust response with a minimum of unpleasant or embarrassing side effects.
For example, researchers are as yet unsure whether sustained use of bremelanotide will end up doing what the drug was meant to do in the first place, and bestow on its beaming clients a truly healthy tan.
Taiwan’s rapid economic development between the 1950s and the 1980s is often attributed to rational planning by highly-educated and impartial technocrats. Those who look at history through blue-tinted spectacles argue that, for much of the post-war period, the government was staffed by Chinese who fled China after the Chinese Nationalist Party (KMT) lost the civil war “who had no property interests in Taiwan and no connections with a landlord class,” leaving “the KMT party-state more autonomous from societal influences than governments [elsewhere in East Asia],” writes Gaye Christoffersen in Market Economics and Political Change: Comparing China and Mexico. At the same
It’s impossible to write a book entirely in the Taokas language. There are only about 500 recorded words in the Aboriginal tongue, whose speakers shifted to Hoklo (also known as Taiwanese) generations ago while preserving certain Taokas phrases in their speech. “When I first started recording the language around 1997, I really had to jog the memories of the elders to find anything,” says Liu Chiu-yun (劉秋雲) a member of the Taokas community and a language researcher. The Taokas last month unveiled a picture book, Osubalaki, Balalong Ramut the community’s first-ever commercial publication using the language. The lavishly illustrated book
In his 1958 book, A Nation of Immigrants, then US senator from Massachusetts John F Kennedy wrote the following words: “Little is more extraordinary than the decision to migrate, little more extraordinary than the accumulation of emotions and thoughts which finally lead a family to say farewell to a community where it has lived for centuries, to abandon old ties and familiar landmarks, and to sail across dark seas to a strange land.” As an epithet, the book’s title is commonly associated with America and, in the face of the xenophobic rhetoric that has marked US President Donald Trump’s tenure,
It seems that even the filmmakers don’t know what happened in 49 Days (驚夢49天). After spending too much of the film building up the mystery and constantly introducing confusing elements, they wrap up the film in the last couple of minutes in the laziest way, with the protagonist actually uttering “nobody knows.” That is bloody annoying, having sat through over 90 minutes of disjointed and head-scratching storytelling. Billed as a horror flick featuring the chilling Taoist ritual of guanluoyin (觀落陰), or visiting hell, 49 Days was meant to scare the pants off viewers over Dragon Boat Festival weekend. Horror movies